Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07537894 · ClinicalTrials.gov registry record · Phase 2
Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07537894: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT07537894 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07537894, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
People seeking second-trimester dilation and evacuation (D\&E) procedures are often facing profoundly challenging circumstances, including desired pregnancies complicated by fetal anomalies or demise, serious maternal health conditions, or changes in financial or relationship status. Although abortion regret is uncommon, the emotional burden surrounding these experiences is substantial: many patients experience significant grief and post-traumatic stress symptoms in the weeks to months following care. Perioperative interventions that decrease the body's stress response offer a promising opportunity to reduce downstream psychologic morbidity. Dexmedetomidine has been shown to reduce PTSD symptoms in other high-stress medical and surgical settings. The investigators are undertaking a randomized trial to evaluate whether perioperative administration of dexmedetomidine during second-trimester D\&E can reduce the frequency and severity of post-procedural grief, directly addressing an unmet need in patient-centered, trauma-informed abortion care.
Interventions
- DRUG Placebo
- DRUG Dexmedetomidine (IV) 0.5 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07537894
The ClinicalTrials.gov registry entry for NCT07537894 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07537894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07537894 about?
NCT07537894 is a clinical study titled "Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation". People seeking second-trimester dilation and evacuation (D\&E) procedures are often facing profoundly challenging circumstances, including desired pregnancies complicated by fetal anomalies or demise, serious maternal health conditions, or changes in financial or relationship status. Although aborti...
What is the current status of trial NCT07537894?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07537894?
The interventions under investigation include: Placebo (DRUG), Dexmedetomidine (IV) 0.5 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT07537894?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.